About Precise Bio
Precise Bio is a company based in Winston-salem (United States) founded in 2015 by Shay Soker, Aryeh Batt, and Anthony Atala. Precise Bio has raised $12 million across 3 funding rounds from investors including ZEISS. The company has 6 employees as of December 31, 2022. Precise Bio offers products and services including Precise Bio Platform and Ophthalmology Unit. Precise Bio operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Collplant, Triastek and ROKIT Healthcare, among others.
- Headquarter Winston-salem, United States
- Employees 6 as on 31 Dec, 2022
- Founders Shay Soker, Aryeh Batt, Anthony Atala
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Precise Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12 M (USD)
in 3 rounds
-
Latest Funding Round
$12 M (USD), Series B
Jan 17, 2024
- Investors
-
Employee Count
6
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Precise Bio
Precise Bio offers a comprehensive portfolio of products and services, including Precise Bio Platform and Ophthalmology Unit.
Integrated system for bio-fabricating tissues and organs using patient cells.
Dedicated unit for eye-related bio-fabrication and tissue engineering.
People of Precise Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Precise Bio
Precise Bio has successfully raised a total of $12M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Precise Bio
Precise Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include ZEISS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of diversified optics for microscopic instruments, medical imaging systems and more
|
Locked | Locked | Locked |
Investor details for Precise Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Precise Bio
Investment portfolio details for Precise Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Precise Bio
Detailed financials for Precise Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Precise Bio Comparisons
Peer comparison for Precise Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Precise Bio
Precise Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Collplant, Triastek and ROKIT Healthcare, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
3D bioprinters and bioinks are developed for research applications.
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| Locked | Locked | Locked |
Provider of 3D printing pharmaceutical technology platform for drug design
|
|
| Locked | Locked | Locked |
4D bio-printer solutions for tissue regeneration are provided.
|
Detailed competitors of Precise Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Precise Bio
Complete news archive for Precise Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Precise Bio
Precise Bio was founded in 2015 and raised its 1st funding round 7 years after it was founded.
Precise Bio is headquartered in Winston-salem, United States. It is registered at Winston-salem, North Carolina, United States.
Aryeh Batt is the current CEO of Precise Bio. They have also founded this company.
Precise Bio is a funded company, having raised a total of $12M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Precise Bio is 6.
Precise Bio was founded in 2015 in Winston-Salem, United States. An integrated 3D printing and tissue-engineering platform is developed for the regenerative medicine sector. Repeatable bio-fabricated organs are produced from patients own cells, targeting cardiology, orthopedics, dermatology, and additional areas. The lead product, a 3D cardiac tissue patch, is implanted post-myocardial infarction to restore cardiac muscle viability and functionality.
Precise Bio's top competitors include Nuclera Nucleics, Allevi and Collplant.
Precise Bio offers Precise Bio Platform and Ophthalmology Unit.
Precise Bio has 1 investor. Key investors include ZEISS.